PUBLIC CONTRACT · 2025
Aquisição de I171, I949 e T1717
- Contract value
- €6,092.28
- Signed on
- 22 September 2025
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 11752265PUBLISHED SUBJECT
1700/2025- Aquisição de I171- Irinotecano (conc p/ sol p/ perf) [100mg/5ml; frs], I949- Irinotecano [300 mg/15 ml; conc p/ sol p/ perf; frs] e T1717- Tocilizumab [162 mg/0.9 ml; sol inj; seringa] - doentes em tratamento.
Parties involved
- Place of performance
- Portugal, Aveiro, Santa Maria da Feira
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- FRESENIUS KABI PHARMA PORTUGAL, LDA. · Tax ID 504293753
Values and timeline
- Contract price
- €6,092.28
- Procedure base price
- €6,703.08
- Total effective price
- Not reported on Portal BASE
- Publication date
- 29 September 2025
- Award date
- 18 September 2025
- Signing date
- 22 September 2025
- Performance period
- 122 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Monofator
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 24.º, n.º 1, alínea e), subalínea ii) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- Not stated
- Centralised procedure
- Yes
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 7804615
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.